- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2523EUR$2,789USD£2,156GBP
- Report
- February 2026
- 200 Pages
United States
From €2704EUR$2,990USD£2,311GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1357EUR$1,500USD£1,159GBP
- Report
- July 2024
- 150 Pages
Global
From €3392EUR$3,750USD£2,899GBP
- Report
- June 2024
- 200 Pages
Global
From €7191EUR$7,950USD£6,145GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1131EUR$1,250USD£966GBP
- Report
- May 2024
- 133 Pages
Global
From €3617EUR$3,999USD£3,091GBP
- Report
- October 2023
- 105 Pages
Global
From €3500EUR$4,145USD£3,096GBP
- Report
- July 2026
- 50 Pages
Global
From €2397EUR$2,650USD£2,048GBP
Somatotropin is a type of endocrine and metabolic disorder drug used to treat growth hormone deficiency. It is a synthetic form of human growth hormone, which is produced naturally in the body and is responsible for growth and development. Somatotropin is used to treat growth hormone deficiency in children and adults, as well as other conditions such as Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. It is also used to treat short stature associated with certain genetic disorders. Somatotropin is administered via injection and is available in both brand-name and generic forms.
Some companies in the Somatotropin market include Pfizer, Novo Nordisk, Eli Lilly, Merck, and Sandoz. Show Less Read more
